Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2007 December;59(4) > Minerva Urologica e Nefrologica 2007 December;59(4):407-11

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

ORIGINAL ARTICLES  


Minerva Urologica e Nefrologica 2007 December;59(4):407-11

language: English

Serum ceruloplasmin as a marker in prostate cancer

Fotiou K. 1,2, Vaiopoulos G. 1, Lilakos K. 1, Giannopoulos A. 3, Mandalenaki K. 4, Marinos G. 3, Koritsiadis G. 3, Sourdis J. 5, Konstantinidou E. 5, Konstantopoulos K. 1

1 Division of Medicine I, Laikon General Hospital, University of Athens School of Medicine Athens, Greece
2 Division of Medicine, General Hospital of Preveza, Preveza, Greece
3 Division of Surgery I, Laikon General Hospital University of Athens School of Medicine Athens, Greece
4 Immunology Unit, Agia Sophia Children’s Hospital, Athens, Greece
5 Division of Mathematics and Genetics Agricultural University of Athens, Athens, Greece


PDF  


Aim. Serum acid phosphatase and prostate specific antigen have been utilized as disease markers in prostate cancer, one of the commonest cancers of the elderly. Serum ceruloplasmin (Cp) increases in cancer patients; it may be a reliable marker for prostate cancer, but few data are available on specificity and sensitivity of Cp values.
Methods. Serum prostate specific antigen (PSA) and Cp was determined in Greek patients suffering from histologically proven prostate carcinoma or benign hyperplasia. The results were compared with those in controls matched for sex and age.
Results. In all studied subjects with a prostate cancer, serum Cp values were higher than age-matched healthy controls; they were also higher in cases with benign hyperplasia. No difference in serum Cp was noted among patients with earlier and advanced stages of the tumor. No difference in Cp was also found between benign hyperplasia and normal controls. There exists a significant difference in serum PSA between both prostate cancer and benign hyperplasia cases. There exists also a difference between benign hyperplasia cases and controls.
Conclusion. It is suggested that serum Cp may complement the biochemical screening in prostate carcinoma, especially in cases where this cancer is not accompanied by elevation of serum PSA. However, it is not of help in differentiating prostate cancer from prostate benign hyperplasia.

top of page

Publication History

Cite this article as

Corresponding author e-mail